文献速递淋巴瘤造血干细胞移植与细胞治疗

抗CD30 CAR-T细胞治疗CD30阳性淋巴瘤的短暂缓解与显著毒性:一项1期试验结果

Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.
PubMed 文献 · Blood Adv · 2024-01-01

这项1期剂量递增试验评估了新型抗CD30 CAR-T(5F11-28Z)治疗复发难治CD30阳性淋巴瘤的安全性与可行性。21例患者(20例经典型霍奇金淋巴瘤、1例间变性大细胞淋巴瘤)接受氟达拉滨/环磷酰胺预处理后输注5F11-Ts。总缓解率43%,仅1例完全缓解,中位无事件生存13周;因毒性试验提前终止,作者认为疗效低、毒性大限制其进一步开发。

要点

  • 21例CD30阳性淋巴瘤患者中总缓解率43%,仅1例达完全缓解,中位无事件生存13周。
  • 11例(52%)发生细胞因子释放综合征,1例为3级,无4/5级;9例(43%)出现新发皮疹。
  • 5例(24%)出现恢复≥30天的3/4级血细胞减少,其中2例(9.5%)长期血细胞减少并并发危及生命的脓毒症,试验因毒性提前终止。

核心结论

  • 5F11-Ts疗效低且毒性显著,限制了其进一步开发。

研究设计与样本

  • 1期剂量递增临床试验,评估5F11-28Z转导T细胞(5F11-Ts)的安全性与可行性,共21例CD30阳性淋巴瘤患者接受输注。
  • 患者于-5至-3天接受环磷酰胺300 mg/m2或500 mg/m2联合氟达拉滨30 mg/m2预处理,第0天输注5F11-Ts。
  • 21例中20例为经典型霍奇金淋巴瘤,1例为间变性大细胞淋巴瘤;中位既往治疗线数7线,中位代谢肿瘤体积66.1 mL(范围6.4-486.7 mL)。
  • 试验注册号NCT03049449。

主要发现

  • 总缓解率43%;1例患者达完全缓解;中位无事件生存13周。
  • 11例(52%)发生细胞因子释放综合征(CRS),其中1例为3级CRS,无4/5级CRS;神经毒性轻微。
  • 9例(43%)出现新发皮疹,2例(9.5%)因长期严重皮疹接受延长疗程糖皮质激素治疗。
  • 5例(24%)出现恢复时间≥30天的3/4级血细胞减少,其中2例(9.5%)长期血细胞减少且病程并发危及生命的脓毒症。
  • 中位血CAR+细胞峰值26个/μL(范围1-513个/μL),但淋巴结活检中未检测到CAR+细胞浸润。

局限性

  • 试验因毒性提前终止。
  • 5F11-Ts疗效低且毒性显著,限制其进一步开发。
  • 淋巴结活检中未检测到CAR+细胞浸润。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

New treatments are needed for relapsed and refractory CD30-expressing lymphomas. We developed a novel anti-CD30 chimeric antigen receptor (CAR), designated 5F11-28Z. Safety and feasibility of 5F11-28Z-transduced T cells (5F11-Ts) were evaluated in a phase 1 dose escalation clinical trial. Patients with CD30-expressing lymphomas received 300 mg/m2 or 500 mg/m2 of cyclophosphamide and 30 mg/m2 of fludarabine on days -5 to -3, followed by infusion of 5F11-Ts on day 0. Twenty-one patients received 5F11-T infusions. Twenty patients had classical Hodgkin lymphoma, and 1 had anaplastic large-cell lymphoma. Patients were heavily pretreated, with a median of 7 prior lines of therapy and substantial tumor burden, with a median metabolic tumor volume of 66.1 mL (range, 6.4-486.7 mL). The overall response rate was 43%; 1 patient achieved a complete remission. Median event-free survival was 13 weeks. Eleven patients had cytokine release syndrome (CRS; 52%). One patient had grade 3 CRS, and there was no grade 4/5 CRS. Neurologic toxicity was minimal. Nine patients (43%) had new-onset rashes. Two patients (9.5%) received extended courses of corticosteroids for prolonged severe rashes. Five patients (24%) had grade 3/4 cytopenias, with recovery time of ≥30 days, and 2 of these patients (9.5%) had prolonged cytopenias with courses complicated by life-threatening sepsis. The trial was halted early because of toxicity. Median peak blood CAR+ cells per μL was 26 (range, 1-513 cells per μL), but no infiltration of CAR+ cells was detected in lymph node biopsies. 5F11-Ts had low efficacy and substantial toxicities, which limit further development of 5F11-Ts. This trial was registered at www.clinicaltrials.gov as #NCT03049449.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Brudno JN, Natrakul DA, Karrs J, et al. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood Adv. 2024. PMID: 37939262. doi:10.1182/bloodadvances.2023011470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。